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Abstract
Background: Medulloblastoma is the most common malignant brain tumor in children. Despite recent improvements in
cure rates, prediction of disease outcome remains a major challenge and survivors suffer from serious therapy-related side-
effects. Recent data showed that patients with WNT-activated tumors have a favorable prognosis, suggesting that these
patients could be treated less intensively, thereby reducing the side-effects. This illustrates the potential benefits of a robust
classification of medulloblastoma patients and a detailed knowledge of associated biological mechanisms.
Methods and Findings: To get a better insight into the molecular biology of medulloblastoma we established mRNA
expression profiles of 62 medulloblastomas and analyzed 52 of them also by comparative genomic hybridization (CGH)
arrays. Five molecular subtypes were identified, characterized by WNT signaling (A; 9 cases), SHH signaling (B; 15 cases),
expression of neuronal differentiation genes (C and D; 16 and 11 cases, respectively) or photoreceptor genes (D and E; both
11 cases). Mutations in b-catenin were identified in all 9 type A tumors, but not in any other tumor. PTCH1 mutations were
exclusively identified in type B tumors. CGH analysis identified several fully or partly subtype-specific chromosomal
aberrations. Monosomy of chromosome 6 occurred only in type A tumors, loss of 9q mostly occurred in type B tumors,
whereas chromosome 17 aberrations, most common in medulloblastoma, were strongly associated with type C or D
tumors. Loss of the inactivated X-chromosome was highly specific for female cases of type C, D and E tumors. Gene
expression levels faithfully reflected the chromosomal copy number changes. Clinicopathological features significantly
different between the 5 subtypes included metastatic disease and age at diagnosis and histology. Metastatic disease at
diagnosis was significantly associated with subtypes C and D and most strongly with subtype E. Patients below 3 yrs of age
had type B, D, or E tumors. Type B included most desmoplastic cases. We validated and confirmed the molecular subtypes
and their associated clinicopathological features with expression data from a second independent series of 46
medulloblastomas.
Conclusions: The new medulloblastoma classification presented in this study will greatly enhance the understanding of this
heterogeneous disease. It will enable a better selection and evaluation of patients in clinical trials, and it will support the
development of new molecular targeted therapies. Ultimately, our results may lead to more individualized therapies with
improved cure rates and a better quality of life.
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Introduction
Medulloblastoma is a highly invasive primitive neuroectodermal
tumor of the cerebellum. It is the most common malignant
embryonal brain tumor in childhood with a peak incidence in the
eighth year of life, but a significant proportion occurs in young
adults and some even in elderly patients [1]. Current treatment
includes surgical resection, radiotherapy and chemotherapy. Cure
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rates are improving, but survival is still poor and survivors suffer
from serious long-term side effects of the therapy. Medulloblas-
toma patients are either classified as standard-risk patients (.3
years of age, non-metastatic disease and a totally or near-totally
resected tumor) or otherwise as high-risk patients [1]. This risk
stratification is unsatisfactory in predicting outcome, with under-
or over-treatment as possible consequences. An improved disease
sub-classification is therefore urgently required. In addition, a
better insight into the molecular biology of medulloblastoma may
lead to the development and application of novel therapies.
Cytogenetic studies and comparative genomic hybridization
(CGH) studies have identified many chromosomal aberrations in
medulloblastomas. Most frequent is isochromosome 17q, often in
combination with loss of 17p, that is found in 30–50% of the cases
[2–7]. These studies also identified high level amplifications of
MYC family members in 5–15% of the cases, which is associated
with a poor outcome [8]. Other proposed prognostic classifiers are
expression of MYC, TRKC, ERBB2, nuclear localization of b-
catenin or a large cell/anaplastic histology [9–18]. Mutations in
Sonic Hedgehog (SHH) pathway genes (PTCH1, SUFU) are found
in approximately 25% of medulloblastomas, and in WNT
pathway genes (b-catenin, APC, AXIN) in approximately 15% of
the cases [17,19–23].
Early gene expression profiling studies, using serial analysis of gene
expression, identified the homeobox gene OTX2 as highly expressed
and occasionally amplified in medulloblastoma [24–28]. The first
microarray studies of medulloblastoma series used a supervised
approach to identify differentially expressed genes after grouping for
metastatic status, histology or survival [29]. Recent microarray
analyses used an unsupervised approach to identify different
molecular subtypes in medulloblastoma [30]. The most distinct
subtype identified in this study was characterized by activation of the
WNT signaling pathway, in most cases due to mutations in the b-
catenin gene [30]. A second subtype, not completely separated from
all other medulloblastomas in their cluster analyses, was found to be
enriched in mutations in either PTCH1 or SUFU and was
characterized by activation of the SHH signaling pathway [30].
Other observed groups were not further characterized.
To further improve the molecular classification of medulloblas-
toma, we have studied a series of 62 medulloblastomas at the
mRNA expression level by Affymetrix HG-U133 plus2.0 Gene-
Chips and characterized genomic abnormalities in a sub-set of
these (n = 52) by comparative genomic hybridization (CGH)
analysis using 30 K oligonucleotide arrays. This integrated
approach identified 5 molecular subtypes of medulloblastomas,
each with a characteristic gene signature, specific clinicopatholog-
ical features and some distinctive genetic aberrations.
Materials and Methods
Tissue samples and DNA/RNA preparation
In total 62 medulloblastoma samples were selected for
Affymetrix gene expression profiling. The set included 60 primary
tumors and 2 local relapses. Patient/tumor characteristics are
presented in Table 1 for the whole series and in Table S1 for each
sample separately. All samples were snap frozen in the institutional
pathology departments immediately upon arrival. All samples
were reviewed by experienced neuropathologists and examined for
tumor content. Samples were excluded from analysis when less
than 70% of the sample contained tumor cells. RNA and DNA
was isolated using Trizol (Invitrogen, Carlsbad, CA). RNA
purification was performed using the RNeasy mini kit (Qiagen,
Germantown, USA). DNA and RNA quantity and quality was
determined by spectrophotometry (Nanodrop, Wilmington, USA)
and microfluidics-based electrophoresis (Agilent 2100 Bioanalyzer,
Agilent, Palo Alto, USA).
Expression profiling
Four mg total RNA was used for hybridization of Affymetrix HG-
U133 plus 2.0 Genechips according to the manufacturer’s
instructions (Affymetrix Inc. Santa Barbara, USA). Quality of the
arrays was ensured by inspection of the beta-actin and GAPDH 59-
39 ratio’s as well as the percentage of present calls generated by the
MAS5.0 algorithm (Affymetrix Inc. Santa Barbara, USA). For
clustering and gene expression analyses data were normalized using
the gcRMA algorithm in the Bioconductor package (http://www.
bioconductor.org) of the R statistical environment (http://www.r-
project.org/). Present call information from the MAS5.0 algorithm
was added to the gcRMA gene expression measures. Expression data
have been deposited in NCBI’s Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through
GEO Series accession number GSE10237. Expression profiles (.cel
files) generated for the 46medulloblastomas published by Thompson
et al. [30] were kindly provided by Dr. Richard Gilbertson. They
were also normalized using the gcRMA algorithm. Present call
information came from the MAS5.0 algorithm.
Expression data analysis
Affymetrix data showed for 43628 probe sets a present call in at
least one of the tumors. They correspond to 17425 different genes.
Unsupervised two-way hierarchical clustering and bootstrap
analysis of tumor samples and expression data was performed
with the TMEV program using Pearson correlation [31]. We used
for clustering only one probe set per gene (the one with the highest
average signal) and only probe sets with a present call in at least
Table 1. Patient/tumor characteristics of medulloblastoma
series used for expression profiling in this study.
Tumor samples
Primary tumors 60
Local relapses 2
Sex
Male 41
Female 21
Histology
Classic 46
Desmoplastic 13
LCA 1
ND 2
Age
Median (range) 6.0 (1.5–35.3)
#3 yr 14
.3 and #18 yr 41
.18 yr 6
ND 1
Metastatic stage
M0 42
M1 7
.M2 9
ND 4
doi:10.1371/journal.pone.0003088.t001
Medulloblastoma Subtypes
PLoS ONE | www.plosone.org 2 August 2008 | Volume 3 | Issue 8 | e3088
one of the tumors. Furthermore, we selected for clustering the
smallest set of genes with the greatest variance in expression
(variance filter in TMEV program) that showed the most robust
cluster result with the highest support from the bootstrap analysis.
Genes specifically expressed in each cluster of tumors found with
cluster analysis were identified by comparing each cluster with all
other tumors. For this we used the student t-test, corrected for
multiple testing using the false discovery rate. Differentially expressed
genes were categorized in GeneOntology groups using the DAVID
tool (http://david.abcc.ncifcrf.gov/). Parametric analysis of geneset
enrichment (PAGE) was performed for GeneOntology groups using
the methods described by Kim and Volskey [32].
Statistics
The CHI-square test was used to test the significance of clinical
differences between subtypes. For differences in age at diagnosis
we used the non-parametric Kruskal-Wallis test.
CGH arrays
For 52 of the 62 medulloblastoma samples DNA was available for
array CGH analysis. DNA quantity and quality was measured
spectrophotometrically (Nanodrop, Wilmington, USA). Samples
with an A260/230 ratio below 1.8 were not used for CGH analysis.
For labeling 300 ng DNA was used, which was mixed with 300 ng
labeled reference DNA of female origin. Labeled DNA was
hybridized to Code-link glass slides which were spotted with
60mer oligonucleotides representing 28830 unique genes designed
by Compugen (San Jose, CA, USA). Labeling, hybridization, and
data analysis was all done according to the methods described by van
den IJssel et al. [33]. The CGH array data were processed with the
CGH-call algorithm in Bioconductor [34]. This algorithm generates
amplified/neutral/deleted calls for all the probes on the CGH
arrays. These calls were subsequently grouped on their cytoband
position. The call which was most often encountered within a
cytoband was recorded. All regions with gain were annotated as ‘+1’
(red) and regions with loss as ‘21’ (green). Regions without
aberrations were annotated as ‘0’ (white). We then performed a
one-way hierarchical cluster analysis of these data for each molecular
subtype separately. For this the TMEV program and Pearson
correlation was used [31].
The CGH-call algorithm does not take chromosomes X and Y
into account. Therefore, data for the X and Y chromosome were
visualized in a different way. For all probes assigned to
chromosome 1–22 the log2 ratio ch1/ch2 was recorded.
Unassigned probes and probes assigned to the sex-chromosomes
X and Y were not included. Subsequently, the median signal over
all these probes was calculated. Data for all probes (including the
probes from X and Y chromosome) were normalized by
subtracting the median signal of probes from chromosome 1–22.
Data for chromosome X and Y for each tumor were then
visualized by plotting the average signal for chromosome X probes
against the average signal for chromosome Y probes.
Mutation analysis
PTCH1, b-catenin, HRAS, KRAS, and NRAS were sequenced
using Big Dye Terminator v1.1 chemistry (Applied Biosystems,
Applera France, Courtaboeuf, France). For PTCH1 all 23 exons
were sequenced. For b-catenin only exon 3 was sequenced. For
HRAS, KRAS and NRAS exons containing codon 12, 13 and 61
were sequenced. Primer sequences can be found in Table S3.
Sequencing was performed on an ABI 3730 capillary sequencer
(Applied Biosystems, Applera France, Courtaboeuf, France).
Forward and reverse sequences on electropherograms were
analyzed using Codon Code aligner (Dedham, MA, USA).
Results
Expression profiling identifies 5 molecular subtypes in
medulloblastoma
We analyzed gene expression profiles of 62 medulloblastoma
samples using Affymetrix HG-U133 plus 2.0 GeneChips. Patient
and tumor characteristics are summarized in Table 1 and detailed
in Table S1. Unsupervised two-way hierarchical cluster analysis
identified 5 clusters, named A, B, C, D and E, consisting of 9, 15,
16, 11 and 11 samples, respectively (Figure 1A). Bootstrap analyses
support differences between all 5 clusters, but clusters A and B
stand out most clearly, while clusters C, D and E are more related
to each other (Figure S1A and S1B). The specific characteristics of
each molecular subtype are described below and are summarized
in Figure 2.
Cluster A is characterized by WNT and TGF-beta signaling
The smallest cluster of 9 tumors (cluster A, marked red in
Figure 1) differed most strongly from all other tumors (Figure 1B).
Many genes of the WNT pathway were overexpressed, including
AXIN2, LEF1, WIF1, KREMEN, DKK1, DKK2, DKK4, WNT11
and WNT16 (Figure 3A and Table S2). Several of them are
inhibitors of the WNT pathway and are upregulated in a
negative feedback loop upon pathway activation. Also known
targets of the WNT pathway, like MYC, RUNX2, GAD1 and SP5
were highly expressed in this group. The WNT pathway is
known to be activated in a subset of medulloblastomas by b-
catenin mutations [22,35–37]. Indeed, mutations were found in all
9 tumors of cluster A, resulting in amino acid changes at
positions 32, 33, 34, or 37 of the b-catenin protein. No such
mutations were found in any of the other 53 samples (P,0.0001)
(Figure 1A and Table S1). This cluster therefore corresponds to
the medulloblastoma subtype with WNT pathway activation and
b-catenin mutations identified by Thompson et al. [30] and
Clifford et al. [38] (see also below). Further characteristics of this
cluster were exclusive expression or overexpression of members
of the TGFb pathway, like BMP4, BMP7, BAMBI, AMHR2,
SMAD3, TGFBI and INHBA.
Cluster B is marked by SHH signaling and low levels of
OTX2
Cluster B (15 samples, marked blue in Figure 1) is
characterized by the overexpression of genes involved in SHH
signaling such as PTCH1, BOC, and GLI2 (Figure 2 and 3B and
Table S2). HHIP and GLI1 were also upregulated, but without
reaching the statistical cut-off of P,0.001. Also known targets of
the SHH signaling pathway such as SFRP1 and BCL2 were
exclusively expressed or upregulated in this cluster. Activation of
the SHH signaling pathway in medulloblastoma can occur by
mutations in PTCH1 [19,39,40]. Sequencing of all 23 exons of
the PTCH1 gene indeed identified frameshift mutations in 4
tumors of cluster B, but not in any of the remaining tumors
(P = 0.009) (Figure 1A and Table S1 for mutation details).
Interestingly, the oncogene OTX2, which is amplified in a low
percentage of medulloblastomas, but highly expressed in about
75% of medulloblastomas [26–28], is not or hardly expressed in
group B tumors (Figure 3B).
Clusters A and B share increased expression of genes
involved in protein biosynthesis, cell cycle, NOTCH and
PDGF pathways
Although tumors from cluster A and B were very distinct from
each other, they also share certain characteristics (Figure 2).
Medulloblastoma Subtypes
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Comparison of the combined 24 samples of the A and B cluster
against all 38 other tumors identified 1484 genes significantly
higher expressed in A and B (p,0.001) (Table S2). Major
pathways recognized amongst them were the NOTCH and PDGF
pathways. Genes like NOTCH1, NOTCH2, DLL3,MNFG, MAML1
and MAML2 were higher expressed in clusters A and B, although
differences did not always reach the statistical cut-off (p-values
between 0.05 and 0.001). For the PDGF signaling pathway we
found increased expression of PDGFA, PDGFC, and PDGFRA in
tumors of clusters A and B (Figure 3C). Also cell cycle genes (e.g.
CDK2 and CDK2AP1) and the protein biosynthesis machinery (e.g.
ribosomal proteins) were upregulated (Figure 2 and 3C). Only
cluster E also showed increased expression of cell cycle and protein
biosynthesis genes (see below).
C, D and E tumors
Tumors in clusters C, D and E are closely related. They fall apart
in three clusters, based on expression of a series of neuronal
differentiation genes in clusters C and D and expression of retinal
differentiation genes in clusters D and E (see below and Figure 2).
Comparison of all 38 tumors in clusters C, D, and E together with
the 24 samples of the A and B cluster identified 1595 genes higher
expressed in C, D, and E (Table S2). However, we did not detect
signaling pathways or biological processes that were specifically
activated in all tumors of the C, D and E clusters. Amongst the genes
specifically expressed in all three clusters C, D and E were two
transcription factors involved in brain development, FOXG1B and
EOMES. Also LEMD1, a testis specific gene recently found to be
overexpressed in colorectal cancer [41] and several genes involved in
Figure 1. Identification of molecular subtypes in medulloblastoma. A. Unsupervised two-way hierarchical cluster analysis of 62
medulloblastoma samples and expression data of 1300 most differentially expressed genes identified 5 distinct clusters indicated as A, B, C, D, and E.
Clinical annotations are at the bottom. Histology: grey = desmoplastic, orange= large cell/anaplastic, white = classic; sex: pink= female, white =male;
Metastatic disease at diagnosis indicated with M stage: yellow=M1, orange=$M2, white =M0; Age: purple = age #3 yrs, white = age .3 yrs; b-
catenin mutations: brown=mutations, white =wild type; PTCH1 mutations: blue =mutations, white =wild type. A cross means not analyzed. B.
Schematic pentagram showing the correlations between the 5 molecular subtypes of medulloblastoma. Numbers at the outside near each subtype
indicate number of genes that are significantly differently expressed between that subtype and all other subtypes (P,0.001). Numbers at connecting
lines indicate number of genes that are significantly differently expressed between medulloblastoma subtypes.
doi:10.1371/journal.pone.0003088.g001
Medulloblastoma Subtypes
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neuronal migration, like UNC5D and EPHA8, were specific for all
tumors in clusters C, D and E (Figure 3C and Table S2).
Cluster C and D are marked by increased expression of
neuronal differentiation genes
Genes identified as overexpressed in cluster C were in most
cases also overexpressed in cluster D, but not in cluster E (Table
S2). Characteristic for these genes was that they were usually not
completely silent in other clusters, but expressed at a lower level.
Gene Ontology analysis showed that many overexpressed genes in
C and D tumors were involved in neuronal differentiation (NNAT,
NEOROD2, RTN1, RTN4R, NEURL, NPAS2, DPYSL5), cytoskel-
eton organization and biogenesis (MPP3, MAST1, MAP2) or
vesicle mediated transport (VAMP4, DNM1, DNM3). Also
members of the glutamate (GRM1, GRM2, GRM8) and GABA
receptor family (GABBR2) were highly expressed in cluster C and
D (Figure 3D and Table S2). Parametric analysis of geneset
enrichment (PAGE) showed that several members of the MAPK
signaling pathway, such as KRAS, DUSP4, DUSP5, GRB2, FGF1,
FGF9, FGF13, and FGF14 were expressed at higher levels in C and
D tumors. As RAS mutations have been found at a low frequency
in medulloblastomas [42], we sequenced the KRAS, NRAS, and
HRAS genes for codon 12, 13 and 61. However, no such mutations
were found in tumors from cluster C or D, nor in any other tumor,
which is consistent with recent data from Gilbertson et al. [43].
Interestingly, the cell cycle inhibitor CDKN1C (P57) was not or
hardly expressed in any tumor of cluster C and D, but is well-
expressed in tumors of cluster E and most other tumors of clusters
A and B (Figure 3D). PAGE analysis also showed that many other
cell cycle related genes, such as CCNB1, CCNB2, CDK6, CDKN2C,
were more weakly expressed in C and D tumors than in tumors of
clusters A, B, and E (Figure 2). These analyses suggest that the
cluster C and D tumors express a set of genes marking a certain
neuronal differentiation stage or lineage and have relatively low
cell cycle activity.
Cluster D and E are marked by expression of retinal
genes
When we compared the combined 22 tumors of cluster D and E
with the 40 tumors of all other clusters, we found 197 genes
significantly overexpressed in D and E (Table S2). A striking
number of them were genes normally expressed in photoreceptor
cells in the retina (Figure 2). Retina-specific transcription factors,
such as NRL, CRX and NR2E3 were expressed at moderate to high
levels in the D and E clusters, but not in any other cluster
(Figure 3E). Other genes encoding retinal antigens like ROM1,
SAG (S-antigen), AIPL1, RPGRIP1, TULP1, and PDE6H were also
exclusively expressed in cluster D and E.
Comparison of the E cluster with the D cluster showed E-
specific expression of a series of genes like SMARCD3 and GABRA5
(Figure 3F). In addition, PAGE analysis showed that E tumors
have an enriched expression of ribosomal protein genes and genes
functioning in the cell cycle, amino-acyl tRNA biosynthesis and
pyrimidine metabolism (Figure 2 and Figure S2).
Figure 2. Schematic overview of the 5 molecular subtypes of medulloblastoma and their molecular, genetic, and clinical
characteristics described in this paper.
doi:10.1371/journal.pone.0003088.g002
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Array CGH analysis reveals subtype-specific DNA copy
number aberrations
For 52 of the 62 tumors sufficient high quality DNA was
available for analysis by CGH arrays (type A: 4 samples, type B: 14
samples, type C: 13 samples, type D: 11 samples, type E: 10
samples). Many aberrations were detected with these arrays and
the different subtypes show distinct patterns of gains and losses
(Figure 4). All 4 analyzed tumors with a WNT signature (type A)
lost a full copy of chromosome 6, but none of the other 48 tumors
did (p,0.001). These data are consistent with data from
Thompson et al. [30] and Clifford et al. [38]. Type B tumors
(SHH type) showed frequent loss of 9q sequences (8/14 samples).
In other clusters this occurred in only 3 other tumors (p = 0.001).
Clusters C, D and E often showed gain of chromosome 18 (11/34
samples; p = 0.012), which was never found in clusters A and B.
Gain of chromosome 17q, often in combination with deletion of
chromosome 17p, was strongly associated with tumors in clusters
C and D (13/24 samples; p = 0.002). Loss of chromosome 8 was
exclusively found in tumors of clusters C and D (7/24 samples;
p = 0.007). Gain of chromosomes 2, 4, 5, 7, 9, 12, 13, and 21 or
parts of them, was also frequently found but they were not
restricted to any particular subtype. This was also the case for the
loss of regions on chromosomes 1, 11, 16, 19, and 22.
Interestingly, in almost every subtype there seemed to be 2 groups
of tumors: one group with very few aberrations and one group
with many aberrations (Figure 4). Furthermore, we identified
several high level amplifications of genes such as MYCN, MYC, or
MYCL1. These amplifications occurred at low frequency and no
statistically significant correlation was observed with any of the
different subtypes.
Loss of one of the X chromosomes (average logratio,20.1) was
found in 10/17 tumors of female patients (Figure 5A). In contrast,
none of the tumors of male patients lost an X chromosome. XIST,
which is specifically expressed from the inactivated X chromosome,
was not or hardly expressed in 9/10 samples with loss of X, indicating
that they lost the inactivated copy of the X chromosome (Figure 5B).
The other sample showed reduced XIST levels. Figure 5B also shows
XIST levels for 4 other female cases not analyzed by CGH. Strikingly,
9 out of 10 cases with almost complete loss of XIST expression were
medulloblastomas from clusters C, D and E (p=0.034). Only one of
the analyzed female cases of cluster D retained 2 copies of the X
chromosome and had highXIST expression. In the combined clusters
A and B, only 1/9 tumors of female origin had lost the expression of
XIST due to the loss of a copy of the X chromosome. Loss of the Y
chromosome occurred in 5 out of 34 analyzed male samples and was
not restricted to any subtype (Figure 5A).
Figure 3. Examples of marker genes. For each medulloblastoma subtype A, B, C, D, and E, the expression data (vertical axes) are shown in each
tumor (indicated with colored circles) for 2 markers that are specifically expressed or upregulated in that subtype, and 2 markers that are not
expressed or only at very low levels in that subtype. A. Type A markers; B. Type B markers; C. In 2C markers are shown that are expressed either in
subtype A and B together or in subtype C, D, and E together; D. Type C and/or CD markers; E. Type DE markers; F. Type E markers.
doi:10.1371/journal.pone.0003088.g003
Medulloblastoma Subtypes
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Chromosomal copy number changes correspond to
strong expression differences
We finally performed an integrated analysis of expression data
and DNA copy number data. A major question that we tried to
answer was whether chromosomal gains and losses affect the
overall expression levels of the affected chromosomal domains.
First, we mapped all Affymetrix probe sets to the human genome
sequence. We then performed for each chromosome separately an
unsupervised one-way clustering of all tumor samples using the
data for all expressed genes. Many regions came out as overall
underexpressed or overexpressed and these regions showed a good
correspondence with the CGH-analysis data. A striking example is
chromosome 6 in the group A tumors: All 9 tumors showed about
50% lower expression of most genes of chromosome 6, compared
to the other tumors (Figure 6A). As described above, deletion of
one copy of entire chromosome 6 was confirmed by CGH in 4/4
analysed cases of group A tumors. Also, loss or gain of other
chromosomal regions detected with array CGH, such as 8, 9q,
17p, 17q, or 18, clearly affect gene expression levels in these
domains (Figure S3). Figure 6B shows an example how gene
expression levels are strongly decreased in a tumor with 9q loss
when compared to a tumor without 9q loss. Second, we compared
all chromosomal regions with gain or loss directly with the gene
expression levels in these regions. An overall analysis shows a good
correlation for all chromosomal regions (P,0.0005) (Figure 6C).
Average gene expression levels are higher in regions that are
gained and lower in regions that are lost. This was true when all
regions from all chromosomes were analyzed together, but also
when the data were analayzed per chromosome (Figure S4). These
data suggest that the distinct gene signatures are not only caused
by mutations in signalling pathways, such as b-catenin or PTCH1
mutations, but also by the subtype-specific chromosomal copy
number aberrations.
Metastatic tumors are predominantly found in clusters C,
D, and E, but are not found in cluster A
The 5 molecular subtypes are marked by several clinical
characteristics. The most striking finding was that presence of
metastatic disease at diagnosis was strongly associated with clusters
C, D, and E, as 15 of the 16 cases (94%, p= 0.005) with metastases
were of these subtypes (Figure 1A). In cluster C the frequency was
31% (5/16 patients: 3 M1 and 2$M2), in cluster D this was 27%
(3/11 patients: 1 M1 and 2$M2), while in cluster E this was 70%
(7/10 patients: 3 M1 and 4$M2). For 1 patient of cluster E we
Figure 4. Cluster analysis of genetic aberrations in the different molecular subtypes identified with array CGH. Array probes were
grouped together according to their position in distinct cytobands. Cytobands were then scored in each tumor as gained (+1, red), lost (21, green),
or unchanged (0, white), based on the array CGH data for all probes in a particular cytoband region. Subsequently, these cytoband data for gain, loss
or no change were clustered using an unsupervised one-way hierarchical clustering. This was done for each molecular subtype separately.
doi:10.1371/journal.pone.0003088.g004
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had no information on metastatic state. In contrast, none of the 7
samples of cluster A and only 1 of the 14 (7%; M2) samples of
cluster B, for which data were available, had metastatic disease at
diagnosis.
Age at diagnosis and histology differ between the 5
subtypes
Medulloblastoma mainly affects children and is rare in adults.
The median age at diagnosis for the whole series was 6.0 yrs, but
varied significantly among the 5 subtypes (p = 0.006; Kruskal-
Wallis test). Median age at diagnosis was 10.4 yrs (range 6–20) for
cluster A, 3.0 yrs (range 1.5–35.3) for cluster B, 7.2 yrs (range 3.7–
25.6) for cluster C, 5.9 yrs (range 3–16.6) for cluster D, and 3.8 yrs
(range 2–15) for cluster E. Of the 14 patients below 3 yrs of age, 9
belonged to cluster B, 2 to cluster D and 3 to cluster E
(p = 0.0006). Of the 4 patients of 25 yrs or older, 3 were found
in cluster B and 1 in cluster C.
Also histology was significantly different between the 5 subtypes
(p = 0.046). Most desmoplastic tumors were found in cluster B,
some occurred also in other clusters, but never in cluster A
(Figure 1A). In cluster A all tumors were of classic histology. There
was only one tumor in our series with a large cell anaplastic
histology, which was found in cluster B.
Analysis of independent medulloblastoma dataset shows
same molecular subtypes
Recently, Thompson et al. [30] published the results of an
expression profiling study of 46 medulloblastomas. Their analysis
also identified 5 clusters. One cluster showed WNT-pathway
activation and 5 out of these 6 samples had b-catenin mutations. A
second cluster (9 samples) was associated with SHH signaling and
4 samples had mutations in PTCH1 and 1 in SUFU. A third cluster
of 13 samples also included 4 tumors with an activated SHH
signaling, one of them with a PTCH1 mutation as well. However,
the other clusters were not described in detail. The clustering of
Thompson et al. did not identify clusters associated with metastatic
disease at diagnosis, suggesting that the clusters identified in their
study were not identical to the clusters identified in our study. The
approach of Thompson et al. differed in two aspects from our
study: 1) They used the Affymetrix HG-U133A GeneChip, while
we used the more recent Affymetrix HG-U133 plus2.0 array, with
twice as many probe sets; 2) Thompson et al. used expression
values of all probe sets for clustering, while we used a set of most
differentially expressed genes. We therefore decided to re-analyze
the data of Thompson et al. using the approaches described in this
paper.
We first clustered the Thompson data on basis of the 1500
genes/probe sets most differentially expressed in that series (note
that these are not the same probe sets used in our study, as the
HG133A chip has fewer probe sets). This analysis identified 4
distinct clusters, supported by bootstrap analysis (Figure 7 and
Figure S5). T-tests performed to compare each cluster with the
other 3 clusters showed that the first 3 clusters corresponded to our
clusters A (6 samples), B (14 samples) and C (12 samples), while the
remaining 14 tumors that grouped together corresponded to our D
and E tumors (see Figure S6). Cluster A represented all WNT-
signature samples. Interestingly, all samples for which Thompson
et al. showed an SHH signaling profile, now clustered together in
the B cluster. The data also suggested that the number of D type
tumors is relatively low in the Thompson series. Expression of
marker genes such as GABRA5, SMARCD3, PLXNC1, DCC, and
FGF9 (Figure 2 and Figure S6 and data not shown) strongly
suggested that most tumors in the combined D/E cluster
correspond to the E type. This is also illustrated by the strong
association (p = 0.0009) of 17p deletions with tumors in cluster C
Figure 5. CGH analysis of sex chromosomes. A. One copy of chromosome X is lost in most female cases of clusters C, D, and E. The plot shows
array CGH data for the X and Y chromosome in males and females of the different subtypes. The plotted data represent the average logratio for
probes on chromosome X vs chromosome Y after normalization on the median of autosomes (see methods). The error-bars represent the standard
error of the mean. Open circles represent male patients, closed circles are for female patients. Colors correspond to the colors for the different
subtypes as indicated in Figure 1. B. XIST expression (vertical axis) is shown for 21 female cases (indicated with colored circles) in the MB62 series. 17
of them were analyzed by CGH arrays (Figure 5A). XIST expression is lost or strongly reduced in most type C, D, or E tumors, but not in type A or B
tumors.
doi:10.1371/journal.pone.0003088.g005
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Figure 6. Genetic aberrations affect gene expression. A. Expression data suggest loss of chromosome 6 in all 9 tumors of cluster A. A one-way
unsupervised hierarchical clustering of 62 medulloblastoma samples is shown for all expressed genes on chromosome 6. Colors on top correspond
with the colors of the different subtypes as shown in Figure 1. Genes on the vertical axis are not clustered and are placed next to each other
according to their position on the chromosome. B. Example of how DNA alterations affect gene expression. Chromosome 9 array CGH data (green)
and expression data (Z-scores, red), both plotted on the Y-axis, are shown for two samples. MB0313 has no DNA alterations for chromosome 9, and
MB0270 has lost the telomeric part of 9q. C. Overall analysis shows how genetic aberrations affect gene expression. Cytoband regions for all tumors
analyzed by array CGH were marked as ‘21’ for loss, ‘0’ for no change, and ‘+1’ for gain. Then the average expression (average Z-scores) of all
expressed genes in these regions was calculated for each tumor and plotted on the Y-axis for each category. Results show that genes in regions with
loss are on average expressed at lower levels (green box) and genes in regions with gain at higher levels (red box), compared to regions with no
changes (blue box). Numbers at the X-axis between brackets represent the number of probe sets that were taken into account per category.
doi:10.1371/journal.pone.0003088.g006
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Figure 7. Unsupervised two-way hierarchical cluster analysis of 46 medulloblastoma samples and expression data of 1500 most
differentially expressed genes from Thompson data series [30]. The clustering identified 4 distinct clusters indicated as A, B, C, and DE.
Clusters D and E could not be separated in this series. Clinical annotations are at the bottom. Thompson subtypes as indicated in their paper:
yellow=Thompson subtype A, light pink = Thompson subtype B, blue= Thompson subtype C, green= Thompson subtype D, dark pink = Thompson
subtype E; Histology: grey = desmoplastic, orange= large cell/anaplastic, white = classic; sex: pink = female, white =male; M stage: yellow=M1,
orange=$M2, white =M0; Age: purple = age #3 yrs, white = age .3 yrs; b-catenin mutations: brown=mutations, white =wild type; PTCH1/SUFU
mutations: light blue= PTCH1 mutations, dark blue= SUFU mutation, white =wild type; 17p deletions: dark red= yes, white = no. A cross means not
analyzed.
doi:10.1371/journal.pone.0003088.g007
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(Figure 7), which is in line with our results that chromosome 17
aberrations are frequently found in type C and D tumors, but not
or much less frequent in type A, B, or E tumors (Figure 4). These
results show that similar subtypes are identified in both data sets
and that the differences in clustering in the Thompson study and
our study depend on the number of genes used for clustering and
to some extend on differences in size and composition of both
tumor series.
As a second comparison of the analyses, we also clustered the
data from the Thompson series using the 1500 probe sets selected
in our series. However, not all of these probes sets are present on
the Affymetrix HG133A chip. Cluster analysis with expression
data of the 897 probe sets that are present identified the same 4
clusters (A, B, C and D/E) in the Thompson dataset, which was
supported by bootstrap analysis. Only one sample (JCO24) moved
from cluster C to cluster D/E (Figure S7).
Clinical characteristics in molecular subtypes are similar
in both medulloblastoma datasets
Analysis of patient data for the 4 molecular subtypes we
identified in the Thompson dataset confirmed our results for
differences in metastasis, histology and age at diagnosis (Figure 7).
Metastatic disease at diagnosis was observed with frequencies of
0% for cluster A, 36% for cluster B, 42% for cluster C and 71%
for cluster D/E. Although the percentage of metastasis for cluster
B is higher than in our series, these data fully confirm the
identification of cluster C and D/E as tumors with the highest
propensity for metastasis (p = 0.024), especially as most tumors in
the D/E cluster probably represent the E type. The E type tumors
are in both series strongly associated with metastatic disease at
diagnosis. Tumors of cluster A clearly are devoid of metastases at
diagnosis. As in our series, most desmoplastic tumors in the
Thompson series were found in cluster B (9/14, p = 0.0031).
Finally, also in the Thompson dataset, all patients below 3 years of
age were found either in cluster B or D/E (p= 0.011) (Figure 7).
Discussion
The clinical behavior of medulloblastoma cannot be fully
understood without detailed knowledge of the intrinsic molecular
biology. Here, we analyzed expression profiles in 62 tumors and
DNA copy number alterations in 52 of them. We show that there
are at least 5 distinct molecular subtypes (Figure 1 and 2). We
validated and confirmed these data in an independent dataset of
46 medulloblastomas generated by Thompson et al. [30], with the
exception that subtype D was underrepresented in their series and
could not be separated from subtype E (Figure 7). Our data clearly
demonstrate that medulloblastoma is a heterogeneous disease.
Each subtype has its own characteristic gene-signature caused by
different genetic aberrations and by mutations in pathway-specific
genes as found for type A and B tumors. It is also apparent from
our data that some characteristic signatures are present in more
than one subtype. For instance, tumors in clusters C, D, and E are
closely related and have partly overlapping expression patterns.
Tumors in clusters C and D have in common that they
overexpress many genes involved in neuronal differentiation and
are low in cell cycle and protein biosynthesis related genes.
Tumors in clusters D and E share a characteristic overexpression
of many retinal antigens, but differ in cell cycle related genes (see
the schematic overview in Figure 2). In contrast to the data of
Thompson et al. [30] we show that not only tumors with WNT
signaling (cluster A), but also tumors with SHH signaling (cluster
B) form separate clusters. However, although distinct in many
aspects, these 2 subtypes share the overexpression of genes
involved in NOTCH and PDGF signaling. They also show an
increased expression of genes involved in cell cycle and protein
biosynthesis like the tumors in cluster E (Figure 2).
Metastasis is associated with neuronal and
photoreceptor specific gene-signatures
Analysis of the 5 clusters for associations with clinicopatholog-
ical parameters showed a striking association with metastatic
disease at diagnosis. Medulloblastoma has a high propensity for
CNS spread and metastatic disease at diagnosis is a strong
indication for poor outcome [44]. Consequently, patients with
metastasis are treated with high-risk protocols. Our study showed
that metastatic disease at diagnosis was strongly associated with
subtypes C, D and especially E, while subtype A tumors never had
metastatic disease at diagnosis. Our analysis is therefore in line
with recent results of Ellison et al. [17] and Gaijar et al. [45] that
medulloblastomas with activated WNT signaling, demonstrated by
nuclear localization of b-catenin, have a favorable outcome and a
very low frequency of metastatic disease at diagnosis. The genes
and/or pathways that control the process of metastasis in
medulloblastoma are largely unknown. Some studies suggested
that increased PDGF signaling is associated with metastatic
medulloblastomas [46,47]. This is not supported by our results,
as PDGF pathway members were mainly expressed in tumors of
clusters A and B (Figure 3E). Comparison of the A and B clusters
versus the C, D and E clusters identified differential expression of a
series of genes with a potential role in neuronal migration and
axon guidance (data not shown). Further analyses are required to
value their role in metastasis.
Desmoplastic tumors associated with young age and
subtype B
The subtypes also differed in histology and median age at
diagnosis. Subtype B tumors frequently showed a desmoplastic
histology and were diagnosed in very young children or adults
(Figure 2). Data from both medulloblastoma series together show
that 16/25 tumors (64%) from infants were classified as type B and
12 of them had desmoplastic histology. The other 9 infants in both
data series were all classified as either type D or E and none of
them had desmoplastic histology (p= 0.0003). Recent reports
suggest that desmoplastic tumors in infants have a very good
prognosis [48–50]. We previously reported that medulloblastomas
lacking expression of the OTX2 oncogene are preferentially of
desmoplastic histology and diagnosed in very young children and
adults [28]. This is in good agreement with our current
observation that OTX2 is highly expressed in all medulloblasto-
mas, except for cluster B tumors.
Photoreceptor gene expression in medulloblastoma type
D and E
A remarkable observation from our study is the expression of
many photoreceptor-specific genes in type D and E tumors. Korf
and colleagues already noticed in 1987 that a subset of
medulloblastomas express S-antigen and opsin, both markers that
are in a non-neoplastic state exclusively expressed in retinal
photoreceptors and a class of pinealocytes which are derivatives of
pineal photoreceptor cells [51,52]. Several other studies confirmed
these results [53–57], but the most recent paper on this topic is
from 1995. Here, we show that not only S-antigen and opsin are
specifically expressed in this subset of medulloblastomas, but many
other photoreceptor-specific genes as well.
Retinal antigens are also expressed in retinoblastoma and
tumors derived from pineal parenchyma (pineocytoma and
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pineoblastoma) [58–61]. This might suggest a common origin of
these tumors and medulloblastomas with retinal antigens. Patients
with hereditary retinoblastoma harboring a mutation in RB1 are at
increased risk of developing pineoblastoma, supratentorial PNET
and there is one case report of a medulloblastoma in such a patient
[62,63]. Although RB1 mutations have never been detected in
other medulloblastomas [64], some experimental tumor models
suggest a role for the RB pathway in this tumor. The combined
loss of p53 and Rb1 in mouse external granular cells of the
cerebellum resulted in medulloblastoma development [64].
Transgenic mice overexpressing SV40 large T-antigen develop,
in addition to abnormal lens fiber differentiation and retinal
dysplasia, also tumors resembling human pineoblastomas and/or
medulloblastomas [65]. Most of these tumors express the
photoreceptor markers S-antigen and opsin [51]. Large T-antigen
can inhibit RB1, resulting in activation of E2F transcription factors
and increased cell proliferation (reviewed by [66]). Recently,
Olson et al. [67] showed that overexpression of E2F1 in glial cells
of transgenic mice also resulted in the induction of medulloblas-
tomas and other PNETs. It will therefore be interesting to analyse
a possible role of the RB1 pathway in medulloblastoma subtypes D
and E with photoreceptor-specific gene expression.
Chromosomal copy number changes strongly affect
gene expression levels
We identified many recurrent chromosomal gains and losses in
specific subtypes, such as the loss of one copy of chromosome 6 in
all type A tumors or the loss of one copy of the X chromosome in
most female cases in type C, D, or E tumors. Such defects suggest
that tumor suppressor genes on these chromosomes play an
important role in the tumorigenesis of these subtypes. However,
our integrated expression and CGH study also showed that
chromosomal copy number changes have a strong effect on the
gene expression levels of almost all genes in the affected
chromosomal areas. For example, this is striking for the expression
of chromosome 6 genes in type A tumors, that have a reduction in
expression equivalent to the reduction in copy number. Evidently,
no compensatory mechanisms exist to increase the expression
levels of most genes on the remaining copy. It is well established
that gain or loss of a full chromosome has very strong
consequences in embryogenesis. It either gives strong develop-
mental defects, or is (as for most chromosomes) not compatible
with life at all. The copy number changes that we observe in
medulloblastoma may therefore also strongly contribute to
pathogenesis. The consistent expression changes that we observed
in the genes of the affected regions, may cause imbalances in the
regulation of many pathways. Our integrated expression and copy
number analysis provide data to further analyse the consequences
of copy number changes for pathway activation or inactivation in
medulloblastoma. In addition, the data might be applied to
identify potential therapeutic target genes, whose role in
tumorigenesis can be investigated with functional assays.
Conclusions
Our study provides an integral overview of genetic aberrations
and molecular pathway activation in medulloblastoma. Analysis of
the expression profiles identifies 5 different types of medulloblas-
toma, each with characteristic activations of pathways and/or
gene-signatures and each associated with specific genetic defects.
These results raise the question whether these five subtypes all
arise from the same cell lineage, but differ due to different genetic
defects, or whether the five subtypes arise from distinct cell types
and lineages. There is strong evidence that medulloblastomas with
a SHH signature originate from progenitor cells of the external
granular layer [68]. It is unknown whether other medulloblasto-
mas also arise from these cells or whether they have another origin
such as the ventricular zone [68]. Comparison of the profiles of the
five medulloblastoma types with future expression profiles of
progenitor cells involved in development of the cerebellum might
answer this question. Regardless of the descent of the five subtypes,
the specific genetic aberrations and the activation profiles of
molecular pathways might help to improve clinical stratification of
tumors and to guide selection of innovative therapies directed to
specific gene products.
Supporting Information
Figure S1 Bootstrap analyses. A. Bootstrap analysis of unsuper-
vised two-way hierarchical cluster analysis (Pearson correlation) of
MB62 data series using the 1300 most differentially expressed
genes. Clusters A and B stand out most clearly, while clusters C, D,
and E are more closely related. With 1300 genes bootstrap support
is 97–100% that the 3 clusters A, B, and C are different from D
and E, but the support for the difference between clusters D and E
is only 21% with this number of genes. When we used 1500 genes
bootstrap support for the difference between E and CD increased
to 72% (see Figure S1B). B. Bootstrap analysis of unsupervised
two-way hierarchical cluster analysis of MB62 data series using the
1500 most differentially expressed genes. With 1500 genes, clusters
A and B still stand out most clearly and bootstrap support is 96–
100% that clusters A and B are different from C, D, and E.
However, in contrast to the results with 1300 genes (Figure S1A),
bootstrap support for the difference between E and CD now
increased to 72%. The support for the difference between C and D
with these 1500 genes is 41%.
Found at: doi:10.1371/journal.pone.0003088.s001 (0.80 MB PPT)
Figure S2 PAGE analysis for clusters D and E in MB62
dataseries shows higher levels of expression for cell cycle genes and
other proliferation related genes in cluster E. Red dots in the
graphs show the average expression for a gene in each cluster. The
grey clouds around each dot indicate the standard deviation of
expression.
Found at: doi:10.1371/journal.pone.0003088.s002 (0.27 MB PPT)
Figure S3 Genetic aberrations suggested by expression data. A
one-way unsupervised hierarchical clustering of 62 medulloblas-
toma samples is shown for each chromosome using all expressed
genes on that particular chromosome. Colors on top correspond
with the colors of the different subtypes as shown in Figure 1. The
genes on each chromosome are not clustered, but are placed
according to their position on the chromosome.
Found at: doi:10.1371/journal.pone.0003088.s003 (3.27 MB PPT)
Figure S4 Genetic aberrations affect gene expression. Cytoband
regions for all tumors analyzed by array CGH were marked as
‘21’ for loss, ‘0’ for no change, and ‘+1’ for gain. Then the
average expression (average Z-scores) of all expressed genes in
these regions was calculated for each tumor and plotted for each
category. Results show that genes in regions with loss are on
average expressed at lower levels (green boxes) and genes in
regions with gain at higher levels (red boxes), compared to regions
with no changes (blue boxes). Numbers at the X-axis between
brackets represent the number of probe sets that were taken into
account per category. Data are shown for each chromosome apart.
Chromosome numbers are shown on top.
Found at: doi:10.1371/journal.pone.0003088.s004 (0.14 MB PPT)
Figure S5 Bootstrap analysis. Bootstrap analysis of unsupervised
two-way hierarchical cluster analysis of MB46 data series of
Thompson et al. [30] using the 1500 most differentially expressed
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genes shows that clusters A, B, C, and D/E are indeed distinct
clusters. Bootstrap support is 88–100% that the 4 clusters are
different from each other.
Found at: doi:10.1371/journal.pone.0003088.s005 (0.43 MB PPT)
Figure S6 Expression data of same selected marker genes from
Figure 3 in molecular subtypes of MB46 data series of Thompson
et al. [30] show that the subtypes identified in the MB46 data
series represent the same subtypes as identified in the MB62 data
series. Expression data (vertical axes) are shown for each tumor
(indicated with colored circles) for each medulloblastoma subtype.
A. Type A markers; B. Type B markers; C. In 2C markers are
shown that are expressed either in subtype A and B together or in
subtype C, D, and E together; D. Type C and/or CD markers; E.
Type DE markers; F. Type E markers. Expression of RUNX2,
OTX2, LEMD1, and ZNF179 cannot be shown for the MB46
data series, since the HG-U133A GeneChip does not contain
probe sets for these genes.
Found at: doi:10.1371/journal.pone.0003088.s006 (0.44 MB PPT)
Figure S7 Cluster analysis. A. Unsupervised two-way hierarchical
cluster analysis of 46 medulloblastomas from Thompson data series
[30] using the 897 genes present at the HG-U133A GeneChip and
present in the 1500 gene dataset selected as most differentially
expressed in the MB62 data series. Results show that also with the
genes selected from the MB62 data series 4 distinct clusters are
identified in the MB46 data series containing the same samples as in
Figure 7. Only one sample (JCO24) switched from cluster C to
cluster D/E. B. Bootstrap analysis of unsupervised two-way
hierarchical cluster analysis of MB46 data series [30] using the 897
genes present at the HG-U133A GeneChip and present in the 1500
gene dataset selected as most differentially expressed in the MB62
data series. The results show that also when these genes are used for
clustering the 4 clusters are distinct clusters.
Found at: doi:10.1371/journal.pone.0003088.s007 (0.33 MB PPT)
Table S1 Patient/tumor characteristics of medulloblastoma
series used for expression profiling in this study.
Found at: doi:10.1371/journal.pone.0003088.s008 (0.03 MB
RTF)
Table S2 Gene-signatures for clusters A–E, and clusters AB vs
CDE, CD vs ABE, and DE vs ABC.
Found at: doi:10.1371/journal.pone.0003088.s009 (1.11 MB
XLS)
Table S3 Primer sequences used for sequencing b-catenin,
PTCH1, HRAS, NRAS, and KRAS.
Found at: doi:10.1371/journal.pone.0003088.s010 (0.03 MB
XLS)
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